Video-urodynamic Improvement of Trigonal BTX-A Injection for Patients with Poor Bladder Compliance Secondary to Spinal Cord Injury

Jiang Zhuocheng¹, Chen Hui^{2, 3,} , Yang XH², Huang MP², Huang TH², Liu QL², Li QQ², Yang XY², Xiao XH², Liu J², Xie Keji⁴ and Jiang Chonghe³

¹Department of Surgery, The Second People's Hospital of Baiyun District, Guangzhou, China

²Department of Urology, Guangdong Provincial Work Injury Rehabilitation Hospital and Jinan University, Guangzhou, China

³Department of Urology, Qingyan City People's Hospital, Jinan University, Guangdong, China

⁴Department of Urology, Guangzhou First Municipal People’s Hospital, Guangzhou, China

Cite this paper

Jiang Zhuocheng, Chen Hui, Yang XH, Huang MP, Huang TH, Liu QL, Li QQ, Yang XY, Xiao XH, Liu J, Xie Keji and Jiang Chonghe. Video-urodynamic Improvement of Trigonal BTX-A Injection for Patients with Poor Bladder Compliance Secondary to Spinal Cord Injury. American Journal of Medical Case Reports. 2018; 6(1):15-17. doi: 10.12691/AJMCR-6-1-5

Abstract

Objective: To evaluate video-urodynamic improvement for trigonal BTX-A injection in patients with neurological poor bladder compliance. Methods: 68 consecutive inpatients with poor bladder compliance secondary to spinal cord injury(SCI) received trigonal injections of BTX-A(300U) into the bladder from June 2014 to February 2017. All were evaluated video-urodynamic outcome included detrusor leak point pressure (DLPP), bladder compliance (BC) and vesicoureteral reflux (VUR) at baseline and 12 weeks post-injection. Results: all outcomes improved significantly compared to baseline. The improvement percentage of DLPP (44.36%) and BC(77.13%). No patient developed unilateral or bilateral VUR. Conclusions: Trigone-including BTX-A injection is safe and effective as the treatment for low BC and does not induce VUR.

Keywords

video-urodynamic, bladder trigone, botulinum toxin A, low bladder compliance, spinal cord injury

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Stöhrer M, Goepel M, Kondo A, et al. The standardization of terminology in neurogenic lower urinary tract dysfunction: with suggestions for diagnostic procedures. International Continence Society Standardization Committee. Neurourol Urodyn. 1999; 18(2): 139-158.
[2]	Gerridzen RG, Thijssen AM, Dehoux E, et al. Risk factors for upper tract deterioration in chronic spinal cord injury patients. J Urol, 1992. 147(2): 416-8.
[3]	Stöhrer M, Blok B, Castro-Diaz D, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol, 2009, 56(1): 81-88.
[4]	Marte A. Onabotulinumtoxin A for Treating Overactive/Poor Compliant Bladders in Children and Adolescents with Neurogenic Bladder Secondary to Myelomeningocele. Toxins 2013; 5(1): 16-24.
[5]	Schurch B, de Sèze M, Denys P,et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol, 2005. 174(1): 196-200.
[6]	Huang M, Chen H, Jiang C, et al. Effects of botulinum toxin A injections in spinal cord injury patients with detrusor overactivity and detrusor sphincter dyssynergia. J RehabilMed. 2016; 48(8): 683-687.
[7]	Citeri M, Spinelli M, Zanollo L, et al. Botulinum toxin into the trigone in neurogenic overactive bladder non-responder to detrusor injection. Eur Urol Suppl 2008; 7: 213.
[8]	Kuo HC. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxin A for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn 2011; 30: 1242-1248.
[9]	Pinto R, Lopes T, Frias B, Silva JA, Silva CM, Cruz C et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol 2010; 58: 360-365.
[10]	Hui C, Keji X, Chonghe J, et al. Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity. Spinal Cord. 2016; 54(1): 46-50.
[11]	Manecksha RP, Cullen IM, Ahmad S, McNeill G, Flynn R, McDermott TE et al. Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxin A for refractory idiopathic detrusor overactivity. Eur Urol 2012; 61: 928–935.
[12]	Conte A, Giannantoni A, Gubbiotti M, et al. Intradetrusorial Botulinum Toxin in Patients with Multiple Sclerosis: A Neurophysiological Study. Toxins.2015; 7(9): 3424-3435.
[13]	Patrick DL, Martin ML, Bushnell DM, et al. Quality of life of women with urinary incontinence: further development of the incontinence quality of life instru ment (I-QOL). Urology19 99; 53:71-76.
[14]	Del Popolo G. Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre. Eur Urol, 2008. 53(5): p. 1013-19.
[15]	Cruz F. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol, 2011. 60(4): p. 742-50.
[16]	Ginsberg D. Phase 3 efficacy and tolerability study of onabotulinumtoxin A for urinary incontinence from neurogenic detrusor overactivity. J Urol, 2012. 187(6): p. 2131-9.
[17]	Grosse J. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol, 2005. 47(5): p.653-9.
[18]	Stöhrer M. Diagnosis and treatment of bladder dysfunction in spinal cord injury patients. Eur Urol Update Series 1994. 3: p. 170-5.
[19]	Castro-Diaz D. Surgery for the neuropathic patient. In Incontinence, P. Abrams, et al., Editors. 2002, Health Publication: Plymouth. p. 865-891.
[20]	Frankel HL. Long-term survival in spinal cord injury: a fifty year investigation. Spinal Cord, 1998. 36(4): p. 266-74.
[21]	Jamil F. Towards a catheter free status in neurogenic bladder dysfunction: a review of bladder management options in spinal cord injury (SCI). Spinal Cord, 2001. 39(7): p. 355-61.
[22]	Schurch B, Stöhrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol, 2000, 164 ( 1):692-697.
[23]	Cohen BL, Barboglio P, Rodriguez D, et al. Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units. Neurourol Urodyn 2009; 28 ( 1): 205-8.
[24]	Klein LA. Urge incontinence can be a disease of bladder sensors. J Urol 1988; 139(5): 1010-1014.